According to Foresight News, Nasdaq-listed LIXTE Biotechnology has announced that its board of directors has approved a strategic capital allocation plan involving cryptocurrency acquisitions. The company plans to allocate 25% of its funds to cryptocurrencies, including Bitcoin and potentially other digital assets, depending on circumstances.